Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 4,833,790

Executive Summary

U.S. Patent No. 4,833,790 (hereafter “the ’790 patent”) was granted on May 23, 1989, and relates to a novel class of aminoglycoside antibiotics, specifically “imidazoline derivatives” with antimicrobial activity. This patent is significant in the landscape of antibiotic development, aiming to enhance efficacy, spectrum, and resistance profile relative to earlier aminoglycosides like gentamicin or tobramycin. The scope encompasses chemical compounds, their synthesis, and pharmaceutical compositions. Its claims primarily cover chemical structures, methods of making these compounds, and their use in bacterial infections.

This analysis provides an in-depth view of the patent’s claims, technological scope, prior art context, and broader patent landscape, to inform strategic patent and R&D considerations.

What is the Scope of U.S. Patent 4,833,790?

Core Invention

The ’790 patent claims a new class of aminoglycoside derivatives characterized by:

An imidazoline ring attached to the aminoglycoside core structure.
Substituents at specific positions that enhance antimicrobial activity.
Methods for synthesis and formulation.

Claim Breakdown

Claim Type	Scope & Content	Key Features
Independent Claims	Cover the chemical compound class and methods of synthesis	Two main classes: (a) chemical structures with specified substitutions, (b) processes for their preparation
Dependent Claims	Narrow down to specific compounds, substitutions, or formulations	Specific substituents, particular stereochemistry, specific bacterial pathogens against which activity is demonstrated

Representative Claims

Claim Number	Scope Summary	Legal Effect
Claim 1	A compound of formula I: an aminoglycoside derivative featuring an imidazoline ring	Broad chemical class; sets foundation for patent monopoly
Claim 2	Specific substitution at R1 and R2 positions	Narrowed scope, emphasizing preferred embodiments
Claim 7	Method of synthesizing the compound from starting materials	Process claims support enabling rights

Chemical Structure & Variability

The core structure involves an aminoglycoside backbone (e.g., gentamicin, kanamycin) with modifications through an imidazoline substitution, which confers:

Altered binding affinity
Reduced resistance
Improved pharmacokinetics

Patent Landscape Context

Historical and Patent Status Overview

Key Patent Timeline Events	Details
Filing Date	August 3, 1984
Grant Date	May 23, 1989
Expiration Date	May 23, 2006 (assuming maintenance up to expiration)
Priority Applications	Filed in multiple jurisdictions (e.g., EP, JP)

Major Related Patents & Literature

Patent / Literature	Focus	Assignee / Author	Publication / Filing Date
US 4,567,039	Additional aminoglycoside derivatives	Schinazi et al.	1984
EP 0 187 848	Variants of aminoglycosides with similar modifications	Schering Corporation	1986
Scientific Literature	Mechanistic insights into modifications’ impact	Johnson et al., 1988	Journals of Medicinal Chemistry

Key Patent Families

The ’790 patent is part of Amyloid series aimed at overcoming resistance and toxicity challenges associated with older aminoglycosides.

Analysis of the Claims' Breadth and Validity

Strengths

The chemical scope covers a broad class of compounds with potential for substantial patent protection.
Method claims provide additional coverage on synthesis pathways.
Claim language emphasizes structural features critical for activity, reducing easy workarounds.

Limitations & Risks

The reliance on chemical modifications may invite design-around strategies.
Prior art, including earlier aminoglycoside derivatives, could challenge the breadth.
The patent’s age indicates expired or near-expiry status (exp.: 2006), expanding open license or generic manufacturing potential.

Potential Infringement & Freedom-to-Operate (FTO)

Companies developing similar aminoglycoside derivatives must review this patent to avoid infringement.
Synthesis pathways or unique substitutions may bypass claims if sufficiently distinct.

Comparison with Contemporary Antibiotic Patents

Parameter	’790 Patent	Contemporary Antibiotic Patents (e.g., US 7,308,763)	Remarks
Scope	Chemical derivatives, synthesis	Broader drug classes, new mechanisms	’790 focused on specific chemical modifications
Patent Term	Until 2006	Typically 20-year term from filing	Expired, no longer enforceable
Innovation Level	Structural modification	Mechanism of action or delivery systems	Older but foundational in aminoglycoside research

Implications for the Current Pharmaceutical Landscape

Patent Expiry: The ’790 patent’s expiration allows generic manufacturers to produce similar derivatives.
Legacy Use: Its chemical backbone and modifications influence newer antibiotics.
Research & Development: Modern derivatives often seek to improve upon the class’s toxicity and resistance issues, possibly inspired by the ’790 modifications.

Most Recent Legal and Regulatory Status

The patent’s expiration aligns with the expiration date, affecting drug patent strategy.
No current active enforcement actions are documented for enforceability.
Generic companies have likely launched products based on the expired patent.

Summary Table: Patent Claims and Landscape

Aspect	Details
Patent Number	4,833,790
Grant Date	May 23, 1989
Expiry Date	May 23, 2006
Focus	Aminoglycoside imidazoline derivatives
Key Claims	Structural class, synthesis, antimicrobial use
Related Patents	US 4,567,039; EP 0 187 848
Patent Family Status	Expired; open for generics
Critical Competitors	Schering, Bristol-Myers, generic manufacturers

Key Takeaways

The ’790 patent extensively claims a class of aminoglycoside derivatives with imidazoline modifications, primarily covering chemical structures and synthesis methods.
Its expiration creates opportunities for generic manufacturers and ongoing research based on its chemical scaffolds.
The patent landscape features related patents that may influence freedom-to-operate.
Future R&D efforts may focus on improving efficacy, resistance profile, and toxicity, inspired by the structural modifications disclosed.
Strategic patent monitoring is essential in this antibiotic class due to global health and regulatory dynamics.

FAQs

Q1: Are compounds similar to the ’790 patent still under patent protection?
A1: No. The ’790 patent expired in 2006, opening the field for generic and biosimilar development.

Q2: What is the scope of the chemical claims in the ’790 patent?
A2: The claims primarily cover aminoglycoside derivatives with an imidazoline ring, including specific substitutions and synthesis methods, providing broad coverage within that chemical space.

Q3: How does the patent landscape for aminoglycoside antibiotics look post-2006?
A3: Post-expiry, many derivatives and formulations are not patent-protected, leading to increased generic competition and ongoing innovation centered on improving safety and efficacy.

Q4: What are the key limitations of the claims in the ’790 patent?
A4: They are limited to specific chemical modifications; minor structural changes outside the claimed scope could circumvent the patent.

Q5: How does this patent impact current R&D strategies?
A5: It provides a foundational chemical framework; researchers can modify or optimize these scaffolds but must ensure patent freedom or pursue new patent filings.

References

U.S. Patent No. 4,833,790.
Scientific literature on aminoglycoside modifications (e.g., Johnson et al., 1988).
Patent landscape reports on aminoglycosides (e.g., WIPO, 2000–2022).
Regulatory filings and patent expiration records (USPTO, 2023).

Note: This analysis is based on publicly available patent data and literature as of 2023. For legal advice or patent prosecution strategies, consult a qualified patent attorney.

Details for Patent: 4,833,790

Summary for Patent: 4,833,790